About this material
This review adapts the editorial article "Mushroom-Based Supplements in Italy: Let's Open Pandora's Box" (MushroomReferences.com, February 2023). The authors examine the Italian mushroom supplement market, its regulation, typical quality problems and risks for the consumer. The Italian case is interesting beyond itself: many of the described problems characterize the European market as a whole.
Market scale
Italy is one of the largest European markets for dietary supplements. According to national manufacturers' associations, the "mushroom" segment (reishi, cordyceps, lion's mane, chaga, maitake and others) showed steady growth in the early 2020s, driven largely by interest in functional nutrition and adaptogens. Demand is fed both by classical mycotherapy and by "natural health" trends.
Regulation and categories
In Italy, as elsewhere in the EU, mushroom supplements fall under integratori alimentari (dietary supplements). This means:
- Not a medicine. The manufacturer cannot claim therapeutic indications — only general formulations like "contributes to normal function of…", "supports…".
- Registration with the Ministry of Health. Each product is registered with its composition, dosages and claimed effects. The register of approved supplements is published on the Ministry's website.
- No medical claims allowed. Unlike drugs, supplements need no efficacy evidence — only confirmation of safety at recommended doses.
This creates a gap between what science says (clinical data for specific fungi and doses) and what a manufacturer may print on the box.
Product quality: the main problems
The MushroomReferences authors and reviews by Italian regulators highlight several typical problems.
Raw-material substitution
- Declared species ≠ real species. Independent checks of Italian and European samples regularly find expensive species declared (reishi, lion's mane) while cheap raw material is actually present (often grain-grown mycelium).
- Mycelium-on-grain vs fruiting body. Most "mushroom" supplements in Europe are actually mycelium grown on grain (rice, oats). The active-compound content of such material is fundamentally lower than in the fruiting body.
Contamination and impurities
- Heavy metals. Wild-harvested fungi (especially chaga, reishi) accumulate arsenic, lead, cadmium, mercury. Without batch-level laboratory control, consumer risks are unacceptable.
- Pesticides. Wild raw material from polluted regions may contain residual pesticides.
- Microbial contamination. With drying and storage violations — moulds, bacteria, mycotoxins.
Label mismatches
- Understated active-compound content. Laboratory checks show actual β-glucan, triterpene or hericenone content often below the declared levels.
- No standardization. The package says "reishi extract" without stating the raw-material:extract ratio, the active-compound profile or the extraction method.
What the consumer can do
Practical recommendations following from the review and the general logic of supplement selection:
- Check the manufacturer. GMP certification, open reports of independent laboratory testing (on the manufacturer's site or independent platforms).
- Read the composition. "Fruiting body extract" ≠ "mycelium on grain". These are different products with different active-compound content.
- Look at standardization. Ideally — a stated percentage of β-glucans, triterpenes or other marker compounds.
- Be wary of "exclusive blends". Blends of 8–10 mushrooms rarely contain a therapeutic dose of each component.
- Wild-harvested material — with caution. Only with a heavy-metal certificate.
What regulators are doing
The Italian Ministry of Health and European regulators (EFSA) are gradually tightening control:
- Expanded lists of banned species. Some species (for example, Amanita species with psychoactive compounds) are under direct prohibition.
- Labeling requirements. Mandatory statement of the raw material (fruiting body / mycelium), country of origin, cultivation method.
- Post-market surveillance. Regular spot checks of products for declared and unwanted components.
Where this material sits in context
- Supplement quality — the general theme. The problems described for Italy apply to most European markets and to the Russian-language segment. Additional context is in Mushroom supplements in integrative oncology, which details the species with human evidence.
- Safety. The general risks of mushroom supplements are in Sources.
- Wood-decay fungi in the catalog. Reishi, Chaga, Lion's mane, Agarikon — species cards with active compounds and clinical data.
Related materials
- Mushroom supplements in integrative oncology — which species have a human evidence base
- Beta-glucans and immunity — general mechanisms and the limits of the evidence base
- Topic: Mushrooms and immunity
- Sources